Results 131 to 140 of about 29,283 (148)

Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease. [PDF]

Clin Pharmacokinet
D'Cunha R, Azam T, Kalabic J, Anschutz T, Lahat A, Pang Y.   +5 more
europepmc   +1 more source

Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome. [PDF]

Eur Heart J Cardiovasc Pharmacother
van den Broek WWA, van den Broek WWA, Azzahhafi J, Chan Pin Yin DRPP, van der Sangen NMR, Sivanesan S, Dijksman LM, Walhout RJ, Tjon Joe Gin M, Breet NJ, Langerveld J, Vlachojannis GJ, van Bommel RJ, Appelman Y, van Schaik RHN, Henriques JPS, Kikkert WJ, Ten Berg JM.   +17 more
europepmc   +1 more source

CYP2C19 Genotype-Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure. [PDF]

Clin Transl Sci
Tunehag KR, Pearce AF, Fox LP, Stouffer GA, Solander S, Lee CR.   +5 more
europepmc   +1 more source

Drug-drug interactions of icenticaftor (QBW251) with a 5-probe cytochrome P450 cocktail and oral contraceptives. [PDF]

Clin Transl Sci
Huth F, Glaenzel U, Drollmann A, Weis W, Zack J, Bebrevska L.   +5 more
europepmc   +1 more source

Clinical impact of pharmacogenetic risk variants in a large chinese cohort. [PDF]

Nat Commun
Wei CY, Wen MS, Cheng CK, Sheen YJ, Yao TC, Lee SL, Wu JY, Tsai MF, Li LH, Chen CH, Fann CS, Yang HC, Huang YT, Chen HH, Liu YM, Yeh EC, Peng YC, Wang SJ, Chen SP, Tsai MT, Huo TI, Su CW, Tarng DC, Huang CC, Fuh JL, Lan KH, Liu YT, Lu CL, Lee YC, Huang YH, Li CP, Wang YF, Hsieh YC, Chen YM, Hsiao TH, Lin CH, Chen YJ, Chen IC, Mao CL, Chang SJ, Chang YL, Liao YJ, Lai CH, Lee WJ, Tung H, Yen TT, Yen HC, Chang JH, Huang CY, Chan L, Lin YW, Hsiao BY, Hu CJ, Lin YK, Lin YF, Chang TC, Wu DC, Kan JY, Hsu CY, Chen SC, Li CC, Huang CF, Sheu CC, Yang LJ, Chen CH, Chen KM, Chang SM, Liou MS, Wang SP, Lin KT, Chuang HP, Chen YJ, Sin J, Chen YT, Chang CC, Kuo CF, Lin JC, Kuo HC, Chan TM, Lee CW, Lai JH, Luo SF, Cheng HT, Lin LY, Chang LC, Tsai CT, Kao HL, Yu JJ, Jeng JS, Chiu MC, Hong TC, Yang SF, Lu HJ, Su SC, Chu P, Li PF, Tsai CL, Tsai CK, Tang SE, Lin CM, Wu YF, Huang CY, Ling SZ, Chang CC, Lin TK, Hsiao SM, Chang CH, Chen CD, Ma GC, Chang TY, Hwang JJ, Lu CL, Kao KJ, Hung CF, Chen SS, Chen PY, Tsui K, Chen YT, Chen CH, Chien CC, Chiang HS, Chiu YL, Chen HC, Kwok PY.   +123 more
europepmc   +1 more source

Antipsychotic and pharmacogenomic effects on cross-sectional symptom severity and cognitive ability in schizophrenia. [PDF]

EBioMedicine
Lock SK, Kappel DB, Owen MJ, Walters JTR, O'Donovan MC, Pardiñas AF, Legge SE.   +6 more
europepmc   +1 more source

Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model.

Health Technol Assess
Carroll J, Lopez Manzano C, Tomlinson E, Sadek A, Cooper C, Jones HE, Rowsell L, Knight J, Mumford A, Palmer R, Hollingworth W, Welton NJ, Whiting P.   +12 more
europepmc   +1 more source

Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome P 450 CYP1A2 and CYP2C19 hydroxylate melatonin

European Journal of Clinical Pharmacology, 2000
The nocturnal serum melatonin (MT) level increases after ingestion of fluvoxamine (FLU)-- a selective serotonin re-uptake inhibitor (SSRI) with antidepressive properties. The mechanism behind the MT increase is unknown. Citalopram (CIT) is another SSRI. It is not known whether CIT affects the serum MT level.
Gunnel Tybring, Sven Röjdmark, Leif Bertilsson, C. von Bahr, Carina Ursing, N. Yasui   +5 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing.

American Journal of Health-System Pharmacy, 2016
PURPOSE The results of a study of variant cytochrome P-450 (CYP) alleles and associated risks of drug-drug interactions (DDIs) and altered drug metabolism are reported.
B. Hocum, J. White, Jarrod W Heck, R. Thirumaran, Nicolas Moyer, R. Newman, K. Ashcraft   +6 more
semanticscholar   +1 more source

: pharmacogenetics; drug toxicity; cytochrome P-450 enzyme system; TPMT; genetic testing

Paediatria Croatica, 2013
Varijabilnosti u učinku lijeka mogu se djelomično objasniti genetičkim razlikama. Postoje interindividualne razlike u metaboličkom itransportnom kapacitetu i detoksikaciji lijekova i drugih ksenobiotika.
Nada Božina, L. Pejnović
semanticscholar   +1 more source